BR112022016054A2 - Composições imunogênicas para coronavírus e usos das mesmas - Google Patents
Composições imunogênicas para coronavírus e usos das mesmasInfo
- Publication number
- BR112022016054A2 BR112022016054A2 BR112022016054A BR112022016054A BR112022016054A2 BR 112022016054 A2 BR112022016054 A2 BR 112022016054A2 BR 112022016054 A BR112022016054 A BR 112022016054A BR 112022016054 A BR112022016054 A BR 112022016054A BR 112022016054 A2 BR112022016054 A2 BR 112022016054A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic compositions
- corona virus
- immunogenic
- corona
- virus
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 3
- 241000711573 Coronaviridae Species 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSIÇÕES IMUNOGÊNICAS PARA CORONAVÍRUS E USOS DAS MESMAS. A presente invenção refere-se a compostos imunogênicos, formulações farmacêuticas dos mesmos e seu uso para a indução de uma resposta imunológica protetora contra a infecção pelo novo coronavírus de 2019 (SARS-CoV-2), e por variantes, em um mamífero.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062977078P | 2020-02-14 | 2020-02-14 | |
US202062992553P | 2020-03-20 | 2020-03-20 | |
US202063005923P | 2020-04-06 | 2020-04-06 | |
US202063016902P | 2020-04-28 | 2020-04-28 | |
US202063050844P | 2020-07-12 | 2020-07-12 | |
US202063069792P | 2020-08-25 | 2020-08-25 | |
US202063088736P | 2020-10-07 | 2020-10-07 | |
US202163140128P | 2021-01-21 | 2021-01-21 | |
US202163142077P | 2021-01-27 | 2021-01-27 | |
US202163148374P | 2021-02-11 | 2021-02-11 | |
PCT/US2021/017920 WO2021163536A2 (en) | 2020-02-14 | 2021-02-12 | Coronavirus immunogenic compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022016054A2 true BR112022016054A2 (pt) | 2022-10-11 |
Family
ID=77295207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022016054A BR112022016054A2 (pt) | 2020-02-14 | 2021-02-12 | Composições imunogênicas para coronavírus e usos das mesmas |
Country Status (12)
Country | Link |
---|---|
US (2) | US20210260180A1 (pt) |
EP (1) | EP4103210A4 (pt) |
JP (1) | JP2023514249A (pt) |
KR (1) | KR20220154121A (pt) |
CN (1) | CN114096675A (pt) |
AU (1) | AU2021220971A1 (pt) |
BR (1) | BR112022016054A2 (pt) |
CA (1) | CA3167833A1 (pt) |
IL (1) | IL295548A (pt) |
MX (1) | MX2022010008A (pt) |
TW (1) | TW202144383A (pt) |
WO (1) | WO2021163536A2 (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114222817A (zh) * | 2019-04-06 | 2022-03-22 | 艾尔特免疫公司 | 广泛且持久的流感疫苗 |
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
CN113336832B (zh) * | 2020-03-02 | 2023-04-18 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白以及含有该蛋白的疫苗 |
CA3172489A1 (en) | 2020-03-23 | 2021-09-30 | Amit KHANDHAR | Nanoemulsion compositions and methods for delivery of nra |
WO2022013609A1 (en) * | 2020-07-13 | 2022-01-20 | Immunovaccine Technologies, Inc. | Sars-cov-2 vaccine compositions and methods of preparation and use |
KR20230092820A (ko) * | 2020-08-22 | 2023-06-26 | 페더럴 스테이트 버지터리 인스티튜션 “내셔널 리서치 센터 포 에피데미올로지 앤드 마이크로바이올로지 네임드 애프터 더 아너러리 아카데미시안 엔.에프. 감마레야” 오브 더 미니스트리 오브 헬스 오브 더 러시안 페더레이션 | Sars-cov-2에 대한 특이적 면역을 유도하기 위한 약제학적 제제 |
US20220193225A1 (en) * | 2020-08-31 | 2022-06-23 | Bruce Lyday | Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins |
MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
US20220348960A1 (en) * | 2021-04-21 | 2022-11-03 | Regents Of The University Of Minnesota | Viral mediated gene delivery for transient expression of proteins |
CN113150085B (zh) * | 2021-04-27 | 2023-04-18 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的组合物 |
CN114560916A (zh) * | 2021-05-18 | 2022-05-31 | 深圳市因诺转化医学研究院 | SARS-CoV-2编码蛋白来源的T细胞表位多肽KLLEQWNLV及其应用 |
WO2022251216A1 (en) * | 2021-05-24 | 2022-12-01 | Epivax, Inc. | T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of beta-coronaviruses |
EP4144751A1 (en) * | 2021-09-01 | 2023-03-08 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | New coronavirus vaccine and method for designing and obtaining a virus vaccine |
WO2023036814A1 (en) * | 2021-09-07 | 2023-03-16 | Universite De Tours | Coronavirus fusion protein |
CN113957097B (zh) * | 2021-09-27 | 2023-11-28 | 中国食品药品检定研究院 | 一种对新冠变异株广谱中和保护的免疫原及其制备方法和应用 |
WO2023070029A1 (en) * | 2021-10-20 | 2023-04-27 | Arizona Board Of Regents On Behalf Of Arizona State University | DNA ORIGAMI SUBUNIT VACCINE FOR PREVENTION OF SARS-CoV-2 VARIANT INFECTION |
CN116350770A (zh) * | 2021-12-28 | 2023-06-30 | 成都迈科康生物科技有限公司 | 一种带状疱疹疫苗制剂及其制备方法 |
RU2765729C1 (ru) * | 2021-12-29 | 2022-02-02 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Иммунобиологическое средство для индукции иммунного ответа против SARS-CoV-2 и способ его применения (варианты) |
WO2023130096A2 (en) * | 2021-12-31 | 2023-07-06 | Boost Biopharma, Inc. | Coronavirus vaccine compositions and uses thereof |
CN114478717B (zh) * | 2022-01-21 | 2022-10-28 | 国药中生生物技术研究院有限公司 | 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用 |
WO2023150638A2 (en) * | 2022-02-02 | 2023-08-10 | Washington University | Omicron coronavirus vaccine constructs and methods of making and using same |
CN116726162A (zh) * | 2022-03-11 | 2023-09-12 | 病毒与疫苗研究中心有限公司 | 用于呼吸道病毒性疾病的疫苗加强组合物 |
CN114702556A (zh) * | 2022-03-22 | 2022-07-05 | 中国人民解放军军事科学院军事医学研究院 | 一种冠状病毒rbd变异体及其应用 |
CN114717205A (zh) * | 2022-03-29 | 2022-07-08 | 中国人民解放军军事科学院军事医学研究院 | 一种冠状病毒RBDdm变异体及其应用 |
CN114574502B (zh) * | 2022-04-11 | 2023-07-14 | 四川大学 | 一种以复制缺陷腺相关病毒为载体的新型冠状病毒疫苗 |
WO2023200858A1 (en) * | 2022-04-13 | 2023-10-19 | The Trustees Of Columbia University In The City Of New York | Inhibitory peptides against coronaviruses |
CN114934056B (zh) * | 2022-06-24 | 2023-10-20 | 仁景(苏州)生物科技有限公司 | 一种基于新型冠状病毒奥密克戎突变株的mRNA疫苗 |
TWI833281B (zh) * | 2022-07-08 | 2024-02-21 | 國防醫學院 | 用於增加基因表現之冠狀病毒核殼蛋白片段及其應用 |
CN115287265B (zh) * | 2022-07-12 | 2023-05-23 | 四川大学华西医院 | 多能活性制剂诱发恒河猴抵抗新冠突变体的免疫防治模型 |
WO2024026553A1 (en) * | 2022-08-03 | 2024-02-08 | Centre Hospitalier De L'université De Montréal | Novel antigenic epitope against sars-cov-2 and uses thereof |
WO2024050451A2 (en) * | 2022-08-31 | 2024-03-07 | Think Therapeutics, Inc. | Compositions and methods for optimized covid peptide vaccines |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000020027A2 (en) * | 1998-10-05 | 2000-04-13 | M & E Biotech A/S | Methods for therapeutic vaccination |
EP3763385A1 (en) * | 2011-03-21 | 2021-01-13 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
AU2013344512B2 (en) * | 2012-11-16 | 2018-06-28 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
GB201708444D0 (en) * | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
WO2021155323A1 (en) * | 2020-01-31 | 2021-08-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines |
US20240123053A1 (en) * | 2020-05-07 | 2024-04-18 | Bharat Biotech International Limited | Coronavirus vaccine through nasal immunization |
-
2021
- 2021-02-12 EP EP21754079.8A patent/EP4103210A4/en active Pending
- 2021-02-12 JP JP2022548966A patent/JP2023514249A/ja active Pending
- 2021-02-12 WO PCT/US2021/017920 patent/WO2021163536A2/en unknown
- 2021-02-12 IL IL295548A patent/IL295548A/en unknown
- 2021-02-12 US US17/175,131 patent/US20210260180A1/en not_active Abandoned
- 2021-02-12 KR KR1020227031741A patent/KR20220154121A/ko unknown
- 2021-02-12 BR BR112022016054A patent/BR112022016054A2/pt not_active Application Discontinuation
- 2021-02-12 CN CN202180001745.8A patent/CN114096675A/zh active Pending
- 2021-02-12 AU AU2021220971A patent/AU2021220971A1/en active Pending
- 2021-02-12 MX MX2022010008A patent/MX2022010008A/es unknown
- 2021-02-12 CA CA3167833A patent/CA3167833A1/en active Pending
- 2021-02-17 TW TW110105306A patent/TW202144383A/zh unknown
- 2021-06-09 US US17/342,769 patent/US11382968B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2021220971A1 (en) | 2022-10-06 |
TW202144383A (zh) | 2021-12-01 |
US20210260180A1 (en) | 2021-08-26 |
EP4103210A2 (en) | 2022-12-21 |
US20220072121A1 (en) | 2022-03-10 |
CA3167833A1 (en) | 2021-08-19 |
EP4103210A4 (en) | 2024-03-20 |
JP2023514249A (ja) | 2023-04-05 |
KR20220154121A (ko) | 2022-11-21 |
US11382968B2 (en) | 2022-07-12 |
WO2021163536A2 (en) | 2021-08-19 |
WO2021163536A3 (en) | 2021-10-21 |
CN114096675A (zh) | 2022-02-25 |
MX2022010008A (es) | 2022-11-14 |
IL295548A (en) | 2022-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022016054A2 (pt) | Composições imunogênicas para coronavírus e usos das mesmas | |
BR112022026321A2 (pt) | Análogos de 1'-ciano nucleosídeo e usos dos mesmos | |
UA98812C2 (ru) | Авирулентная активированная живая вакцина mycoplasma hyopneumoniae | |
ECSP22072586A (es) | VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG | |
HRP20040195B1 (hr) | Cjepivo protiv bolesti zapadnoga nila | |
PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
BR112015014243A8 (pt) | composição de vacina para uso em populações imunocomprometidas e uso da mesma | |
BR112022016507A2 (pt) | Vacinas contra o coronavírus e métodos de uso | |
BR112021019845A2 (pt) | Composições de vírus inativado e formulações de vacina contra zika | |
BR112023005043A2 (pt) | Vacina contra covid-19 à base de piv5 | |
BR112022022859A2 (pt) | Vacinas contra sars-cov-2 | |
EA201700340A1 (ru) | Биологически активное вещество полифармакологического действия растительного происхождения | |
CL2021002582A1 (es) | Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos | |
BRPI0516314A (pt) | uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv | |
BRPI0516542A (pt) | composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária | |
BR112015031226A2 (pt) | Composição de vacina, e, uso da composição de vacina | |
ECSP22081150A (es) | Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica | |
BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
BR112022018504A2 (pt) | Usos de uma composição | |
UY39313A (es) | Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |